Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

Impact · against what's priced in

Hansa Biopharma's financial position is significantly strengthened by a €110 million upfront payment from SERB, extending its runway to roughly 2.5 years. However, this is offset by a concerning drop in core product sales (143.6 MSEK to 80.7 MSEK) and widening net losses, while the FDA IND submission for HNSA-5487 creates a new long-term catalyst.

HNSA+0.50

No priced-in read yet